Pyrimethamine

乙胺嘧啶

Report date: 2023/04/23 15:18:07
NME

Base Information

Drug NamePyrimethamine
Drug Alias Name乙嘧啶溴苄铵息疟定乙胺咪啶利美达民 +[10] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDihydrofolate reductase inhibitors
TargetsDihydrofolate reductase
Therapy Area/IndicationsFamilial Amyotrophic Lateral SclerosisAutoimmune DiseasesLymphoproliferative Disorders +[8] 
Global Approved IndicationsMalariaInfections
Approved Indications in ChinaInfections
Original Approved Country/TerritoryUnited States
Original Approved Date1953/01/23
Country/TerritoryUnited StatesSwedenItaly +[5] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesTuring Pharmaceuticals
China Registration ClassN/A

Develop Information

Active CompaniesDana-Farber Cancer InstitutePhoenixus AGTilde Sciences LLC +[6] 
Inactive CompaniesWeill Medical College of Cornell UniversityNational Institute Of Allergy And Infectious Diseases (Niaid)
Active IndicationsHead and Neck NeoplasmsLeukemia, Lymphocytic, Chronic, B-CellMalaria +[4] 
Inactive IndicationsFamilial Amyotrophic Lateral SclerosisAutoimmune DiseasesLymphoproliferative Disorders +[4] 

Other Information

ATC CodeP01BD01
Related LinksWikipediaDrugBankKEGG